vonjo - pacritinib capsule
(Pacritinib)Sobi, Inc.
Usage: Vonjo treats adults with intermediate or high-risk primary or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia) with a platelet count below 50 × 10⁹/L. Approved under accelerated approval based on spleen volume reduction.